NRXP logo

NRx Pharmaceuticals (NRXP)

Profile

Full Name

NRx Pharmaceuticals, Inc.

Ticker Symbol

NRXP

Exchange

NASDAQ

Country

United States

IPO

December 4, 2017

Indexes

Not included

Employees

2

Key Details

Price

$1.93(0.00%)

Market cap

Last Dividend

-

TTM Dividend yield

-

Annual revenue

-

Annual EPS

-$2.36(+40.70% YoY)

PE ratio

-

Next earnings date

May 14, 2025

Next ex-dividend date

N/A

Next split date

N/A

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price Performance

Price Range

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Shares Outstanding

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

EPS

Profit

Expenses

EBIT & EBITDA

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Liabilities

Debt

Equity & Capital

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

CAPEX

Free Cash Flow

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

ROA & ROE

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Analyst ratings

Recent major analysts updates

Apr 2, 25 BTIG
Buy
Mar 31, 25 D. Boral Capital
Buy
Mar 24, 25 D. Boral Capital
Buy
Mar 20, 25 HC Wainwright & Co.
Buy
Mar 20, 25 D. Boral Capital
Buy
Mar 17, 25 D. Boral Capital
Buy
Mar 14, 25 HC Wainwright & Co.
Buy
Jan 28, 25 D. Boral Capital
Buy
Jan 6, 25 D. Boral Capital
Buy
Jan 2, 25 D. Boral Capital
Buy

Institutional Ownership

  • What is the ticker symbol for NRx Pharmaceuticals?
  • Does NRx Pharmaceuticals pay dividends?
  • What sector is NRx Pharmaceuticals in?
  • What industry is NRx Pharmaceuticals in?
  • What country is NRx Pharmaceuticals based in?
  • When did NRx Pharmaceuticals go public?
  • Is NRx Pharmaceuticals in the S&P 500?
  • Is NRx Pharmaceuticals in the NASDAQ 100?
  • Is NRx Pharmaceuticals in the Dow Jones?
  • When was NRx Pharmaceuticals's last earnings report?
  • When does NRx Pharmaceuticals report earnings?
  • Should I buy NRx Pharmaceuticals stock now?

What is the ticker symbol for NRx Pharmaceuticals?

The ticker symbol for NRx Pharmaceuticals is NASDAQ:NRXP

Does NRx Pharmaceuticals pay dividends?

No, NRx Pharmaceuticals does not pay dividends

What sector is NRx Pharmaceuticals in?

NRx Pharmaceuticals is in the Healthcare sector

What industry is NRx Pharmaceuticals in?

NRx Pharmaceuticals is in the Biotechnology industry

What country is NRx Pharmaceuticals based in?

NRx Pharmaceuticals is headquartered in United States

When did NRx Pharmaceuticals go public?

NRx Pharmaceuticals's initial public offering (IPO) was on December 4, 2017

Is NRx Pharmaceuticals in the S&P 500?

No, NRx Pharmaceuticals is not included in the S&P 500 index

Is NRx Pharmaceuticals in the NASDAQ 100?

No, NRx Pharmaceuticals is not included in the NASDAQ 100 index

Is NRx Pharmaceuticals in the Dow Jones?

No, NRx Pharmaceuticals is not included in the Dow Jones index

When was NRx Pharmaceuticals's last earnings report?

NRx Pharmaceuticals's most recent earnings report was on Mar 17, 2025

When does NRx Pharmaceuticals report earnings?

The next expected earnings date for NRx Pharmaceuticals is May 14, 2025

Should I buy NRx Pharmaceuticals stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions
On this page